|
|
Article: BioSphere Medical Second Quarter Loss Narrows Significantly on 14% Growth in U.S. Embolics and Delivery Systems Revenue.(Financial report)
- Article from:
- Business Wire
- Article date:
- July 29, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Conference Call to Be Held July 30 at 8:30 a.m. Eastern Time
ROCKLAND, Mass. -- BioSphere Medical, Inc. (NASDAQ:BSMD) ("BioSphere" or the "Company") - a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - today reported financial results for the three and six months ended June 30, 2009. Highlights of the second quarter of 2009 and subsequent weeks include:
* Net loss per share was $0.04 during the second quarter of 2009, down sharply from a net loss per share of $0.07 in ...